Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry

Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry

Bibliographic Details
Main Authors:	Hilary M. DuBrock, Charles D. Burger, Sonja D. Bartolome, Jeremy P. Feldman, David D. Ivy, Erika B. Rosenzweig, Jeffrey S. Sager, Kenneth W. Presberg, Stephen C. Mathai, Matthew R. Lammi, James R. Klinger, Michael Eggert, Teresa De Marco, Jean M. Elwing, David Badesch, Todd M. Bull, Linda M. Cadaret, Gautam Ramani, Thenappan Thenappan, H. James Ford, Nadine Al‐Naamani, Marc A. Simon, Sula Mazimba, James R. Runo, Murali Chakinala, Evelyn M. Horn, John J. Ryan, Robert P. Frantz, Michael J. Krowka, PHAR Investigators
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	Pulmonary Circulation
Subjects:	healthcare utilization pulmonary hypertension socioeconomic status
Online Access:	https://doi.org/10.1002/pul2.12172

Similar Items

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
by: Hilary M. DuBrock, et al.
Published: (2021-06-01)

Health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)
by: Jasleen Minhas, et al.
Published: (2021-10-01)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
by: Kevin Y. Chang, et al.
Published: (2022-05-01)

Corrigendum for health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: And analysis from the Pulmonary Hypertension Association Registry
by: J. Minhas, et al.
Published: (2022-04-01)

Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry
by: Shoaib Fakhri, et al.
Published: (2020-11-01)

Impact of the COVID‐19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association Registry
by: Megan Mayer, et al.
Published: (2023-04-01)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Raymond L. Benza, et al.
Published: (2022-10-01)

Pulmonary hypertension associated with congenital portosystemic shunts as a new form of portopulmonary hypertension in children and adults
by: I. M. Miklashevich, et al.
Published: (2024-04-01)

Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes
by: Kathryn T. del Valle, MD, et al.
Published: (2022-12-01)

Hepatopulmonary syndrome and portopulmonary hypertension
by: R Naeije
Published: (2003-03-01)

Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
by: Felipe Kazmirczak, et al.
Published: (2023-07-01)

Portopulmonary hypertension: peculiarities of diagnosis and treatment
by: S.M. Chooklin, et al.
Published: (2024-05-01)

Intermittent Fasting Enhances Right Ventricular Function in Preclinical Pulmonary Arterial Hypertension
by: Sasha Z. Prisco, et al.
Published: (2021-11-01)

Portopulmonary Hypertension: An Updated Review
by: Erick A. Jasso-Baltazar, MD, et al.
Published: (2023-08-01)

Pulmonary hypertension patient perspectives toward pulmonary rehabilitation
by: Morgan Bailey, et al.
Published: (2024-01-01)

Portopulmonary Hypertension: From Bench to Bedside
by: Christopher Thomas, et al.
Published: (2020-11-01)

The Utility of Follow-up Transthoracic Echocardiogram to Screen for Severe Portopulmonary Hypertension (POPH) in Patients Granted POPH Model for End-stage Liver Disease (MELD) Exceptions
by: Kathryn T. del Valle, MD, et al.
Published: (2025-03-01)

Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension
by: Kevin Y. Chang, et al.
Published: (2023-03-01)

Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension
by: Jolene H Fisher, et al.
Published: (2015-01-01)

Portopulmonary hypertension: Success with combined medical treatment
by: María Hernández, et al.
Published: (2023-04-01)

Exercise-Induced Changes in Pulmonary Artery Stiffness in Pulmonary Hypertension
by: Omid Forouzan, et al.
Published: (2019-04-01)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
by: Rodrigo Cartin-Ceba, et al.
Published: (2018-05-01)

Anticoagulation in pulmonary arterial hypertension: a decision analysis
by: Arun Jose, et al.
Published: (2019-12-01)

Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report
by: Bremer Hinrich C, et al.
Published: (2007-07-01)

Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview
by: Jose T. Altamirano, et al.
Published: (2012-09-01)

Clinical outcomes of upfront combination therapy for portopulmonary hypertension
by: Takatoyo Kiko, et al.
Published: (2024-09-01)

Portopulmonary hypertension: advances and challenges in diagnosis and clinical treatment
by: FU Zhigang, QIN Jia, TAN Jiangshan
Published: (2024-08-01)

Current clinical understanding and effectiveness of portopulmonary hypertension treatment
by: Yuichi Tamura, et al.
Published: (2023-04-01)

Pulmonary Hypertension Secondary to COPD
by: Adil Shujaat, et al.
Published: (2012-01-01)

Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database
by: Pamela L. Lutsey, et al.
Published: (2022-07-01)

Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation
by: Dan Grinnan, et al.
Published: (2022-07-01)

Hepatopulmonary Syndrome and Portopulmonary Hypertension in Children: Recent Advances in Diagnosis and Management
by: Lee, Way Seah, et al.
Published: (2018)

Ventricular mass discriminates pulmonary arterial hypertension as redefined at the Sixth World Symposium on Pulmonary Hypertension
by: Catherine E. Simpson, et al.
Published: (2022-01-01)

Diagnosis and Management of Pulmonary Arterial Hypertension
by: Jeanne Houtchens, et al.
Published: (2011-01-01)

Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients
by: Jian Li, et al.
Published: (2018-01-01)

Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation
by: Alex J. Chang, MD, et al.
Published: (2024-03-01)

Overdue to understand anticoagulation in pulmonary arterial hypertension
by: Kishan S. Parikh, et al.
Published: (2018-03-01)

The feasibility and value of assessing patient‐reported outcomes in pulmonary arterial hypertension
by: Hilary M. DuBrock, et al.
Published: (2022-10-01)

Human liver single nuclear RNA sequencing implicates BMPR2, GDF15, arginine, and estrogen in portopulmonary hypertension
by: Arun Jose, et al.
Published: (2023-08-01)

The study of risk in pulmonary arterial hypertension
by: Gerald Simonneau, et al.
Published: (2012-09-01)